Anti-vascular Endothelial Growth Factor, Diabetic Macular Edema, Diabetic Retinopathy
Conditions
Keywords
Diabetic retinopathy, metabolomics, NLPR3, Diabetic Macular edema, Anti-vascular endothelial growth factor
Brief summary
Diabetic retinopathy (DR) is one of the most serious microvascular complications of diabetes. Early diagnosis and treatment of diabetes is the key to prevent visual impairment in DR patients. This study aims to use a non-targeted metabolomics detection technique combined with ultra-high performance liquid chromatography time-of-flight mass spectrometry to analyze the metabolomics profile in aqueous humor sample of DR patents, and further explore the mechanism of the relationship between differential metabolites and their metabolic pathways with NLRP3 activation in DR inflammatory damage. DR patients with macular edema will receive anti-vascular endothelial growth factor (anti-VEGF) treatment; these patients will be divided into two groups: responders group and non-responders group.
Interventions
None listed
Sponsors
Zhongshan Ophthalmic Center, Sun Yat-sen University
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
40 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
1. Patients \> 40 years old. 2. CON (non diabetes control group)：patients undergoing phacoemulsification surgery. 3. NDR (non diabetes retinopathy diabetes patients): patients with diabetes history and undergoing phacoemulsification surgery. 4. NPDR (non proliferative diabetes retinopathy): patients with history of diabetes, fundus microangiopathy shown by fundus fluorescein angiography, including microangioma, hard exudation, wadding exudation and other non proliferative diabetes retinopathy signs, and did not receive invasive ophthalmic treatment within 3 months. 5. PDR (proliferative diabetes retinopathy): patients with a history of diabetes, fundus neovascular lesions shown by fundus fluorescein angiography, and did not receive invasive ophthalmic treatment within 3 months. 6. Patients voluntarily signed informed consent.
Exclusion criteria
1. CON (non diabetes control group)：patients with a history of other ophthalmic operations. 2. NDR (non diabetes retinopathy diabetes patients): patients with fundus changes of diabetes retinopathy or other ophthalmic surgery history. 3. NPDR (non proliferative diabetes retinopathy): patients with fundus neovascular lesions shown by fundus fluorescein angiography. 4. PDR (proliferative diabetes retinopathy):patients undergoing vitrectomy。 5. Patients with active ocular inflammation, high myopia, pregnancy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Untargeted metabolomics for metabolic profile using UHPLC/MS | 24 weeks | Aqueous humor samples in DR patients will be analysed to putatively identify metabolic profile by comparison with control samples using ultra-high performance liquid chromatography-high resolution mass spectrometer (UHPLC/MS). UHPLC/MS analysis allows the simultaneous high-resolution measurement of a broad range of metabolites, hence the untargeted nature of the analysis. For the UHPLC/MS results, perform normalization, standardization, and log transformation, then compare the metabolite differences between groups. Multivariate statistical analysis and Partial least squares discriminant analysis included in the mass spectrometry software will be used to analyse UHPLC/MS results to identify metabolites that best discriminate between DR and control conditions. The evaluation of significant metabolite results is based on: P-value and Fold change. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Best-corrected visual acuity | 24 weeks | Best-corrected visual acuity at baseline and 24 weeks follow-up |
| Central subfield thickness | 24 weeks | Central subfield thickness at baseline and 24 weeks follow-up |
Countries
China
Contacts
Primary ContactHui Chen, PHD
Outcome results
None listed